Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Musculotropic antispasmodic for IBS cramps. | Relieves stomach and period cramps. |
| Body system | Stomach & Gut | Stomach & Gut |
| Drug class | Antispasmodics | Antispasmodics |
| Supply | Pharmacist or prescription | Over the counter |
| Main uses | Irritable bowel syndrome, Gut spasm | Stomach cramps and IBS, Period cramps, Bowel and bladder spasm, Reducing secretions at end of life (injection) |
| How it works | Relaxes cramping muscle in the gut. | Relaxes cramping muscles in the gut. |
| Starts working | 30–60 minutes | — |
| Half-life | Not well defined | — |
| Typical adult dose | 135 mg three times a day, 20 minutes before meals; 200 mg modified-release twice a day. | 10–20 mg up to four times a day. |
| Forms | Tablet, Modified-release capsule, Oral suspension | Tablet, Injection |
| Common side effects | Rash, Headache, Indigestion | Dry mouth, Constipation, Fast heartbeat |
| Serious side effects | Allergic reactions, Angioedema (rare) | Severe heart effects with injection in heart disease, Urinary retention |
| Don't take if | Paralytic ileus; Allergy to mebeverine | — |
| Alcohol | Usually no problem in moderation. No specific interaction. | — |
| Pregnancy | Use with cautionLimited data; use only if needed. | Use with cautionAvoid unless advised. |
| Breastfeeding | Use with cautionLimited data. | — |
| In use since | — | 1951 |
| Brand names | United Kingdom: Colofac, Colofac MRIndia: Colospa, DuspatalinAustralia: Colofac | United Kingdom: BuscopanIndia: Buscopan, SpasmonilAustralia: Buscopan |
| Legal status | United States: Over the counterUnited Kingdom: General sale or pharmacy medicineIndia: Over the counter | — |
| ATC code | A03AA04 | A03BB01 |
Taken together
- ModerateMebeverine + Hyoscine butylbromide: High anticholinergic burden
Adding anticholinergic drugs increases dry mouth, constipation, urinary retention, blurred vision and confusion — and in older people, falls and possibly dementia risk.